Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.430
+0.020 (4.88%)
Mar 10, 2026, 3:15 PM HKT
-27.12%
Market Cap 1.69B
Revenue (ttm) 464.53M
Net Income (ttm) -30.11M
Shares Out 4.12B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,000
Average Volume 102,200
Open 0.450
Previous Close 0.410
Day's Range 0.430 - 0.450
52-Week Range 0.380 - 0.940
Beta 0.94
RSI 23.87
Earnings Date Mar 24, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 383
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

In 2024, Mabpharm's revenue was 258.23 million, an increase of 196.27% compared to the previous year's 87.16 million. Losses were -127.95 million, -38.89% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.